Worth Venture Partners’s Cardlytics CDLX Stock Holding History

Worth Venture Partners’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,774	Closed	-$440K	–	80
2023 Q4	$440K	Sell	4,774 -388	-8%	-$39.4K	0.24%	76
2023 Q3	$852K	Hold	5,162	–	–	0.51%	57
2023 Q2	$326K	Hold	5,162	–	–	0.18%	86
2023 Q1	$175K	Sell	5,162 -5,161	-50%	-$270K	0.09%	132
2022 Q4	$597K	Buy	10,323 +5,161	+100%	+$319K	0.35%	69
2022 Q3	$485K	Buy	5,162 +2,309	+81%	+$329K	0.3%	74
2022 Q2	$403K	Sell	2,853 -333	-10%	-$112K	0.24%	84
2022 Q1	$1.75M	Buy	3,186 +442	+16%	+$267K	0.81%	46
2021 Q4	$1.81M	Buy	2,744 +209	+8%	+$160K	0.9%	39
2021 Q3	$2.13M	Buy	2,535 +110	+5%	+$112K	0.96%	36
2021 Q2	$3.08M	Buy	2,425 +1,012	+72%	+$1.14M	1.14%	32
2021 Q1	$1.55M	Buy	+1,413	New	+$1.87M	0.75%	36

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Worth Venture Partners's CDLX Position: Q1 2024 in Review

Worth Venture Partners sold out of Cardlytics (CDLX) in Q1 2024, closing a stake of 4,774 shares — an estimated $440K sold.

Worth Venture Partners first reported a position in CDLX in Q1 2021 and held it in 12 quarters. The position peaked at $3.08M in Q2 2021. 144 funds tracked by Wall St. Rank hold CDLX as of Q1 2024.

Worth Venture Partners reported no remaining Cardlytics position as of Q1 2024 after selling out during the quarter.
Worth Venture Partners sold 4,774 Cardlytics shares in Q1 2024, an estimated $440K.
Worth Venture Partners first reported a position in Cardlytics in Q1 2021 and held it in 12 quarters.
Worth Venture Partners's Cardlytics position peaked at $3.08M in Q2 2021.
144 funds tracked by Wall St. Rank held Cardlytics as of Q1 2024.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.